Skip to content
Calculator

Women · PCOS

PCOS and GLP-1 drugs: what the trials found

Polycystic ovary syndrome combines insulin resistance, raised androgens and irregular ovulation, and many women with it carry extra weight. GLP-1 drugs are tried for all of these. This page sets out what the randomized trials actually measured, and where the evidence runs out.

Last updated November 3, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Every claim sourced · No products sold, no seller named

📋 Key takeaways

Weight: a modest, short-term benefit. Across 11 randomized trials, adding a GLP-1 drug lowered BMI by 1.38 kg/m² more than the comparison, with low certainty.1

Cycles and androgens: promising for liraglutide, uncertain overall. A liraglutide meta-analysis found more frequent periods and lower androgen markers;2 the broader GLP-1 meta-analysis found the evidence on menstrual regularity and hirsutism insufficient.1

Fertility has barely been measured. Ovulation and pregnancy could not be pooled for lack of reporting.2

If cycles return, so can pregnancy. The contraception and washout rules on the labels matter more in PCOS, not less.67

On this page

  1. What the pooled trials show
  2. Semaglutide and tirzepatide in PCOS
  3. Fertility, contraception and pregnancy
  4. Frequently asked questions
  5. Related on Grey Peptides
  6. Sources

What the pooled trials show

Two meta-analyses published in 2026 answer different questions.

  • All GLP-1 drugs, 11 randomized trials (Forslund 2026). Added to other care, GLP-1 drugs reduced BMI by 1.38 kg/m² (95% CI 0.38 to 2.39) more than the comparison, with low certainty. There was no difference in LDL cholesterol or triglycerides, and the evidence was insufficient to conclude anything about glucose, insulin, hirsutism or menstrual regularity. No trial measured quality of life, mental health or cost-effectiveness.1
  • Liraglutide, 7 randomized trials, 330 women (Lu 2026). Compared with control treatments, liraglutide increased menstrual frequency, reduced BMI and insulin resistance, lowered luteinizing hormone and the free androgen index, and modestly raised sex hormone-binding globulin. Heterogeneity was high for menstrual frequency, and ovulation and pregnancy could not be pooled because too few trials reported them. Side effects were mainly mild gastrointestinal symptoms.2

The two read differently because they pool different trials and outcomes: one asks what any GLP-1 drug adds and grades the certainty, the other pools liraglutide alone (our reasoning, from their methods as described).

Semaglutide and tirzepatide in PCOS

The newer, stronger drugs have the least PCOS-specific evidence. A randomized, placebo-controlled study of semaglutide in women with obesity and PCOS measured taste and brain responses to food rather than PCOS outcomes: taste recognition improved and brain responses to food cues changed.4 For tirzepatide, an open-label trial in 60 Chinese women with PCOS compared low-dose tirzepatide plus metformin with metformin alone for 16 weeks: weight fell 10.4 kg against 1.7 kg, and the return of regular cycles and the pregnancy rate were both higher in the combination group.3 One open-label trial in one population is a start, not a settled answer (our reasoning).

The broader class includes exenatide, which has its own PCOS trials, among them a trial comparing it with dapagliflozin, combinations of the two, dapagliflozin with metformin, and phentermine/topiramate;8 our PCOS and peptides review goes compound by compound, including the research peptides with no PCOS trial at all.

Fertility, contraception and pregnancy

In the tirzepatide trial above, barrier contraception was required during treatment, and pregnancies were followed after participants switched back to metformin alone.3 That design reflects the labels. Zepbound's label says the drug may reduce the efficacy of oral contraceptives in the weeks after starting and after each dose increase, and advises a non-oral or added barrier method.6 Wegovy's label advises stopping at least two months before a planned pregnancy.7 Many women with PCOS use the pill to regulate cycles, so the tirzepatide instruction applies to them directly (our reasoning). See contraception and GLP-1s and pregnancy and planning.

A 2026 systematic review of GLP-1 drugs around conception and pregnancy found early exposure was not consistently linked to malformations, and described GLP-1 drugs in PCOS as promising in various respects.5

Frequently asked questions

Does semaglutide or liraglutide help PCOS?

Pooled trials show modest weight loss, with low certainty. For liraglutide, a 2026 meta-analysis also found more frequent periods and lower androgen markers. Effects on ovulation and pregnancy have not been measured well enough to pool.

Can a GLP-1 drug make me fertile again?

In one open-label tirzepatide trial, cycle recovery and pregnancy rates were higher with tirzepatide plus metformin than with metformin alone. Because pregnancy is possible, follow the labels on contraception and on stopping before a planned pregnancy.

Women, pregnancy and peptides hub Pregnancy and planning a pregnancy Breastfeeding Contraception and GLP-1s Menopause Peptides and women's health Peptides, GLP-1s, pregnancy and breastfeeding PCOS and peptides Peptides for menopause GLP-1 drug interactions Starting a GLP-1

Sources

Studies are cited by PMID and checked on PubMed; labels by their DailyMed set and version. All read November 3, 2026.

  1. Forslund M, et al. GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol 2026;194(3):25-39. PMID 41701618. Source
  2. Lu YT, et al. Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: A systematic review and meta-analysis. Diabetes Obes Metab 2026;28(4):2523-2535. PMID 41508932. Source
  3. Yang Z, et al. Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial. Diabetes Obes Metab 2026;28(8):7380-7392. PMID 42236268. Source
  4. Jensterle M, et al. Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Study. J Clin Endocrinol Metab 2025;111(1):e270-e280. PMID 40341357. Source
  5. Ozbek L, et al. Safety of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes. Diabetes Obes Metab 2026;28(6):4503-4528. PMID 41885132. Source
  6. Zepbound (tirzepatide) US prescribing information (Eli Lilly; DailyMed set 487cd7e7, version 40, effective August 28, 2026), sections 7, 8 and 12. DailyMed
  7. Wegovy (semaglutide) US prescribing information (Novo Nordisk; DailyMed set ee06186f, version 19, effective June 18, 2026), sections 7, 8 and 12. DailyMed
  8. Elkind-Hirsch KE, et al. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab 2021;106(10):3019-3033. PMID 34097062. Source

This section reports what labels, LactMed and published studies say; it is not medical advice, and it does not replace the obstetrician, midwife, prescriber or pharmacist who knows your history. Grey Peptides sells nothing, links to no seller and rates none. If you are pregnant and have taken something you are unsure of, the MotherToBaby service (1-866-626-6847 in the US) answers questions about exposures in pregnancy and breastfeeding.